TABLE 1.
SUCRA value of primary and secondary outcome indicators.
| Treatment | UAER | ORR | Scr | 24 h UTP | HbA1c | TC | Trig | AEs | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUCRA (%) | Mean rank | SUCRA (%) | Mean rank | SUCRA (%) | Mean rank | SUCRA (%) | Mean rank | SUCRA (%) | Mean rank | SUCRA (%) | Mean rank | SUCRA (%) | Mean rank | SUCRA (%) | Mean rank | |
| ACEI/ARB | 2.4 | 9.8 | 0.0 | 10.0 | 3.8 | 9.7 | 18.2 | 5.9 | 16.9 | 6.0 | 0.5 | 8.0 | 3.6 | 7.7 | 58.6 | 4.7 |
| BLC | 62.6 | 4.4 | 27.8 | 7.5 | 54.0 | 5.1 | 78.5 | 2.3 | 40.3 | 4.6 | 58.1 | 3.9 | 97.0 | 1.2 | 80.9 | 2.7 |
| JSB | 54.0 | 5.1 | 38.6 | 6.5 | 75.3 | 3.2 | 69.8 | 2.8 | 77.6 | 2.3 | 24.1 | 6.3 | 39.9 | 5.2 | 42.1 | 6.2 |
| HKC | 51.4 | 5.4 | 55.3 | 5.0 | 39.6 | 6.4 | 33.1 | 5.0 | 81.0 | 2.1 | 44.2 | 4.9 | 58.0 | 3.9 | 32.2 | 7.1 |
| UCG | 98.0 | 1.2 | 45.4 | 5.9 | 55.8 | 5.0 | 43.0 | 4.4 | 16.1 | 6.0 | 65.8 | 3.4 | 50.3 | 4.5 | 46.3 | 5.8 |
| TG | 74.3 | 3.3 | 62.9 | 4.3 | 26.9 | 7.6 | NR | NR | NR | NR | 75.8 | 2.7 | 49.2 | 4.6 | 13.4 | 8.8 |
| CXC | 35.3 | 6.8 | 91.9 | 1.7 | 57.1 | 4.9 | 59.7 | 3.4 | 45.8 | 4.3 | 41.3 | 5.1 | 50.9 | 4.4 | 37.2 | 6.6 |
| SYKFT | 61.0 | 4.5 | 64.3 | 4.2 | 40.7 | 6.3 | NR | NR | NR | NR | NR | NR | NR | NR | 51.8 | 5.3 |
| KLX | 33.9 | 6.9 | 55.7 | 5.0 | 47.7 | 5.7 | 47.7 | 4.1 | NR | NR | 90.2 | 1.7 | 51.0 | 4.4 | 54.5 | 5.1 |
| SSNT | 27.2 | 7.6 | 58.1 | 4.8 | 99.3 | 1.1 | NR | NR | 72.2 | 2.7 | NR | NR | NR | NR | 82.9 | 2.5 |
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BLC, Bailing capsule; JSB, Jinshuibao capsule; HKC, Huangkui capsule; UCG, uremic clearance granule; TG, tripterygium glycosides; CXC, Compound Xueshuantong capsule; SYKFT, Shenyan Kangfu tablet; KLX, Keluoxin capsule; SSNT, Shenshuaining tablet; UAER, urinary albumin excretion rate; ORR, overall response rate; Scr, serum creatinine; 24 h UTP, 24 h urinary total protein; HbA1c, glycosylated hemoglobin, type A1c; TC, total cholesterol; Trig, triglyceride; AEs, adverse effects.